Chronic Idiopathic Urticaria
Conditions
Brief summary
The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult patients aged 12-75 who have been diagnosed with refractory CIU and who remain symptomatic despite standard-dosed H1 antihistamine treatment.
Detailed description
The trial incorporated a Type I error control plan, as follows: The testing of the primary endpoint was conducted in the following hierarchical order. A p-value that is less than 0.05 can only be claimed statistically significant if statistical significance has been claimed at the previous stage. * Stage 1: Omalizumab 300-mg group vs. placebo * Stage 2: Omalizumab 150-mg group vs. placebo * Stage 3: Omalizumab 75-mg group vs. placebo A hierarchical analysis of the secondary endpoints was performed for each dose found to be significant in the primary endpoint. A p-value that is less than 0.05 can only be claimed statistically significant if statistical significance has been claimed at the previous stage. * Stage 1: Change from baseline in Urticaria Activity Score (UAS7) at Week 12 * Stage 2: Change from baseline in the weekly number of hives score at Week 12 * Stage 3: Time to weekly itch severity score Minimally Important Difference (MID) response at Week 12 * Stage 4: Proportion of patients with UAS7 ≤ 6 at Week 12 * Stage 5: Proportion of weekly itch severity score MID Responders at Week 12 * Stage 6: Change from baseline in weekly size of the largest hive score at Week 12 * Stage 7: Change from baseline in overall Dermatology Life Quality Index (DLQI) score at Week 12 * Stage 8: Proportion of angioedema-free days from Week 4 to Week 12
Interventions
DRUGPlacebo
Placebo was supplied lyophilized in vials.
DRUGOmalizumab
Omalizumab was supplied lyophilized in vials.
Sponsors
Genentech, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
12 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) CIU/CSU refractory to H1 antihistamines at the time of randomization.
Exclusion criteria
* Treatment with an investigational agent within 30 days prior to screening. * Weight \< 20 kg (44 lbs). * Clearly defined underlying etiology for chronic urticarias other than CIU. * Evidence of parasitic infection. * Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or other skin disease associated with itch. * Previous treatment with omalizumab within a year prior to screening. * Routine doses of the following medications within 30 days prior to screening: Systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide. * Intravenous (IV) immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to screening. * Regular (daily/every other day) doxepin (oral) use within 6 weeks prior to screening. * Any H2 antihistamine use within 7 days prior to screening. * Any leukotriene receptor antagonist (LTRA) (montelukast or zafirlukast) within 7 days prior to screening. * Any H1 antihistamines at greater than approved doses within 3 days prior to screening. * Patients with current malignancy, history of malignancy, or currently under work-up for suspected malignancy except non-melanoma skin cancer that has been treated or excised and is considered resolved. * Hypersensitivity to omalizumab or any component of the formulation. * History of anaphylactic shock. * Presence of clinically significant cardiovascular, neurological, psychiatric, metabolic, or other pathological conditions that could interfere with the interpretation of the study results and or compromise the safety of the patients. * Evidence of current drug or alcohol abuse. * Nursing women or women of childbearing potential, unless they meet the following definition of post-menopausal: 12 months of natural amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \> 40 milli-international units per milliliter (mIU/mL) or 6 weeks post surgical bilateral oophorectomy (with or without hysterectomy) or hysterectomy or are using one or more of the following acceptable methods of contraception: surgical sterilization, hormonal contraception, and double-barrier methods.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the Weekly Itch Severity Score at Week 12 | Baseline, Week 12 | The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the Weekly Number of Hives Score at Week 12 | Baseline, Week 12 | The weekly hives score is the sum of the daily hives scores over 7 days and ranges from 0 to 21. The number of hives is measured twice daily (morning and evening) on a scale of 0 (none) to 3 (\> 12 hives per 12 hours). The daily hives score is the average of the morning and evening scores. The Baseline score is the sum of the daily hives scores over the 7 days prior to the first treatment. A higher score indicates more hives. A negative change score indicates improvement. |
| Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12 | by Week 12 | The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement. The MID response for weekly itch severity score was defined as a reduction from baseline in weekly itch severity score of 5 points or more. The time to weekly itch severity score MID response was defined as the time (in weeks) from Day 1 to the study week when weekly itch severity score MID response was first achieved. |
| Percentage of Participants With a UAS7 Less Than or Equal to 6 at Week 12 | Week 12 | The urticaria activity score (UAS) is a composite of scores on a scale of 0 (none) to 3 (intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch, measured twice daily (morning and evening). Daily UAS is the average of morning and evening scores (ranging from 0-6) and the UAS7 is the sum of the daily UAS over 7 days (ranging from 0-42). Baseline UAS7 is calculated using data from the 7 days prior to the first treatment date. A higher UAS indicates more urticaria activity. A negative change score indicates improvement. |
| Change From Baseline in the Weekly Urticaria Activity Score (UAS7) at Week 12 | Baseline, Week 12 | The urticaria activity score (UAS) is a composite of scores on a scale of 0 (none) to 3 (intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch, measured twice daily (morning and evening). Daily UAS is the average of morning and evening scores (ranging from 0-6) and the UAS7 is the sum of the daily UAS over 7 days (ranging from 0-42). Baseline UAS7 is calculated using data from the 7 days prior to the first treatment date. A higher UAS indicates more urticaria activity. A negative change score indicates improvement. |
| Change From Baseline in the Weekly Size of the Largest Hive Score at Week 12 | Baseline, Week 12 | The size of the largest hive is assessed twice daily (morning and evening) on a scale of 0 (none) to 3 (\> 2.5 cm). The daily score is the average of the morning and evening scores. The weekly size of the largest hive score is the sum of the daily scores over 7 days, and ranges from 0 to 21. The Baseline weekly size of the largest hive score is the sum of daily scores over the 7 days prior to the first treatment. A higher score indicates larger hives. A negative change score indicates a reduction in hive size. |
| Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) at Week 12 | Baseline, Week 12 | The dermatology life quality index (DLQI) is a 10-item dermatology-specific health-related quality of life measure. Participants rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives on a scale of 0 (Not at all) to 3 (Very much). The overall DLQI is the sum of the responses to the 10 items and ranges from 0 to 30. A lower score indicates a better quality of life. A negative change score indicates improvement. |
| Percentage of Angioedema-free Days From Week 4 to Week 12 | Week 4 to Week 12 | The percentage of angioedema-free days from Weeks 4 to 12 was defined as the number of days a patient reported as angioedema-free in the daily diary divided by the total number of days with a non-missing diary entry, starting at the Week 4 visit and ending the day prior to the Week 12 visit. |
| Percentage of Weekly Itch Severity Score MID Responders at Week 12 | Baseline, Week 12 | The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement. The MID response for weekly itch severity score was defined as a reduction from baseline in weekly itch severity score of 5 points or more. This outcome measure shows the percentage of participants classified as MID Responders at Week 12, meaning their weekly itch severity scores at Week 12 were at least 5 points lower than at Baseline. |
Countries
Denmark, France, Germany, Italy, Poland, Spain, Turkey (Türkiye), United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Placebo administered subcutaneously (sc) every 4 weeks. | 79 |
| Omalizumab 75 mg Omalizumab 75 mg sc every 4 weeks. | 82 |
| Omalizumab 150 mg Omalizumab 150 mg sc every 4 weeks. | 82 |
| Omalizumab 300 mg Omalizumab 300 mg sc every 4 weeks. | 79 |
| Total | 322 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 | 1 | 1 |
| Overall Study | Disease Progression | 0 | 1 | 3 | 6 |
| Overall Study | Lost to Follow-up | 1 | 1 | 2 | 2 |
| Overall Study | Physician Decision | 0 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 3 | 4 | 3 | 3 |
Baseline characteristics
| Characteristic | Placebo | Omalizumab 75 mg | Omalizumab 150 mg | Omalizumab 300 mg | Total |
|---|---|---|---|---|---|
| Age Continuous | 43.1 Years STANDARD_DEVIATION 12.5 | 39.7 Years STANDARD_DEVIATION 15 | 43.0 Years STANDARD_DEVIATION 13.2 | 44.3 Years STANDARD_DEVIATION 13.7 | 42.5 Years STANDARD_DEVIATION 13.7 |
| Sex: Female, Male Female | 55 Participants | 61 Participants | 65 Participants | 63 Participants | 244 Participants |
| Sex: Female, Male Male | 24 Participants | 21 Participants | 17 Participants | 16 Participants | 78 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 35 / 79 | 30 / 76 | 42 / 88 | 35 / 79 |
| serious Total, serious adverse events | 2 / 79 | 1 / 76 | 1 / 88 | 5 / 79 |
Outcome results
Primary
Change From Baseline in the Weekly Itch Severity Score at Week 12
The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement.
Time frame: Baseline, Week 12
Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Weekly Itch Severity Score at Week 12 | -5.14 Units on a scale | Standard Deviation 5.58 |
| Omalizumab 75 mg | Change From Baseline in the Weekly Itch Severity Score at Week 12 | -5.87 Units on a scale | Standard Deviation 6.45 |
| Omalizumab 150 mg | Change From Baseline in the Weekly Itch Severity Score at Week 12 | -8.14 Units on a scale | Standard Deviation 6.44 |
| Omalizumab 300 mg | Change From Baseline in the Weekly Itch Severity Score at Week 12 | -9.77 Units on a scale | Standard Deviation 5.95 |
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 75 mg groups.p-value: 0.463795% CI: [-2.54, 1.16]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 150 mg groups.p-value: 0.001195% CI: [-4.85, -1.24]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 300 mg groups.p-value: <0.000195% CI: [-6.49, -3.13]ANCOVA
Secondary
Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) at Week 12
The dermatology life quality index (DLQI) is a 10-item dermatology-specific health-related quality of life measure. Participants rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives on a scale of 0 (Not at all) to 3 (Very much). The overall DLQI is the sum of the responses to the 10 items and ranges from 0 to 30. A lower score indicates a better quality of life. A negative change score indicates improvement.
Time frame: Baseline, Week 12
Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug and who had a DLQI score at Week 12.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) at Week 12 | -6.09 Units on a scale | Standard Deviation 7.47 |
| Omalizumab 75 mg | Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) at Week 12 | -7.50 Units on a scale | Standard Deviation 7.16 |
| Omalizumab 150 mg | Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) at Week 12 | -8.29 Units on a scale | Standard Deviation 6.31 |
| Omalizumab 300 mg | Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) at Week 12 | -10.15 Units on a scale | Standard Deviation 6.83 |
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 75 mg groups.p-value: 0.120795% CI: [-3.82, 0.45]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 150 mg groups.p-value: 0.021595% CI: [-4.64, -0.38]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 300 mg groups.p-value: 0.000495% CI: [-5.85, -1.73]ANCOVA
Secondary
Change From Baseline in the Weekly Number of Hives Score at Week 12
The weekly hives score is the sum of the daily hives scores over 7 days and ranges from 0 to 21. The number of hives is measured twice daily (morning and evening) on a scale of 0 (none) to 3 (\> 12 hives per 12 hours). The daily hives score is the average of the morning and evening scores. The Baseline score is the sum of the daily hives scores over the 7 days prior to the first treatment. A higher score indicates more hives. A negative change score indicates improvement.
Time frame: Baseline, Week 12
Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Weekly Number of Hives Score at Week 12 | -5.22 Units on a scale | Standard Deviation 6.56 |
| Omalizumab 75 mg | Change From Baseline in the Weekly Number of Hives Score at Week 12 | -7.21 Units on a scale | Standard Deviation 6.96 |
| Omalizumab 150 mg | Change From Baseline in the Weekly Number of Hives Score at Week 12 | -9.75 Units on a scale | Standard Deviation 7.28 |
| Omalizumab 300 mg | Change From Baseline in the Weekly Number of Hives Score at Week 12 | -11.97 Units on a scale | Standard Deviation 7.58 |
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 75 mg groups.p-value: 0.060395% CI: [-4.11, 0.09]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 150 mg groups.p-value: <0.000195% CI: [-6.65, -2.36]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 300 mg groups.p-value: <0.000195% CI: [-9.26, -4.93]ANCOVA
Secondary
Change From Baseline in the Weekly Size of the Largest Hive Score at Week 12
The size of the largest hive is assessed twice daily (morning and evening) on a scale of 0 (none) to 3 (\> 2.5 cm). The daily score is the average of the morning and evening scores. The weekly size of the largest hive score is the sum of the daily scores over 7 days, and ranges from 0 to 21. The Baseline weekly size of the largest hive score is the sum of daily scores over the 7 days prior to the first treatment. A higher score indicates larger hives. A negative change score indicates a reduction in hive size.
Time frame: Baseline, Week 12
Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Weekly Size of the Largest Hive Score at Week 12 | -4.04 Units on a scale | Standard Deviation 5.55 |
| Omalizumab 75 mg | Change From Baseline in the Weekly Size of the Largest Hive Score at Week 12 | -6.52 Units on a scale | Standard Deviation 6.33 |
| Omalizumab 150 mg | Change From Baseline in the Weekly Size of the Largest Hive Score at Week 12 | -7.84 Units on a scale | Standard Deviation 6.75 |
| Omalizumab 300 mg | Change From Baseline in the Weekly Size of the Largest Hive Score at Week 12 | -11.00 Units on a scale | Standard Deviation 7.18 |
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 75 mg groups.p-value: 0.008295% CI: [-4.32, -0.65]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 150 mg groups.p-value: <0.000195% CI: [-5.61, -1.9]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and the omalizumab 300 mg groups.p-value: <0.000195% CI: [-9.03, -5.27]ANCOVA
Secondary
Change From Baseline in the Weekly Urticaria Activity Score (UAS7) at Week 12
The urticaria activity score (UAS) is a composite of scores on a scale of 0 (none) to 3 (intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch, measured twice daily (morning and evening). Daily UAS is the average of morning and evening scores (ranging from 0-6) and the UAS7 is the sum of the daily UAS over 7 days (ranging from 0-42). Baseline UAS7 is calculated using data from the 7 days prior to the first treatment date. A higher UAS indicates more urticaria activity. A negative change score indicates improvement.
Time frame: Baseline, Week 12
Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Weekly Urticaria Activity Score (UAS7) at Week 12 | -10.36 Units on a scale | Standard Deviation 11.61 |
| Omalizumab 75 mg | Change From Baseline in the Weekly Urticaria Activity Score (UAS7) at Week 12 | -13.08 Units on a scale | Standard Deviation 12.67 |
| Omalizumab 150 mg | Change From Baseline in the Weekly Urticaria Activity Score (UAS7) at Week 12 | -17.89 Units on a scale | Standard Deviation 13.23 |
| Omalizumab 300 mg | Change From Baseline in the Weekly Urticaria Activity Score (UAS7) at Week 12 | -21.74 Units on a scale | Standard Deviation 12.78 |
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 75 mg groups.p-value: 0.157595% CI: [-6.53, 1.07]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 150 mg groups.p-value: 0.000195% CI: [-11.49, -3.88]ANCOVA
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 300 mg groups.p-value: <0.000195% CI: [-16.13, -8.66]ANCOVA
Secondary
Percentage of Angioedema-free Days From Week 4 to Week 12
The percentage of angioedema-free days from Weeks 4 to 12 was defined as the number of days a patient reported as angioedema-free in the daily diary divided by the total number of days with a non-missing diary entry, starting at the Week 4 visit and ending the day prior to the Week 12 visit.
Time frame: Week 4 to Week 12
Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug. Patients who withdrew before the Week 4 visit or who had missing responses for more than 40% of the daily diary entries between the Week 4 visit and the Week 12 visit were not included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Percentage of Angioedema-free Days From Week 4 to Week 12 | 89.2 Percentage of days | Standard Deviation 19 |
| Omalizumab 75 mg | Percentage of Angioedema-free Days From Week 4 to Week 12 | 93.5 Percentage of days | Standard Deviation 14.9 |
| Omalizumab 150 mg | Percentage of Angioedema-free Days From Week 4 to Week 12 | 91.6 Percentage of days | Standard Deviation 17.4 |
| Omalizumab 300 mg | Percentage of Angioedema-free Days From Week 4 to Week 12 | 95.5 Percentage of days | Standard Deviation 14.5 |
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 75 mg groups.p-value: 0.1361Stratified Wilcoxon
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 150 mg groups.p-value: 0.0905Stratified Wilcoxon
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 300 mg.p-value: <0.0001Stratified Wilcoxon
Secondary
Percentage of Participants With a UAS7 Less Than or Equal to 6 at Week 12
The urticaria activity score (UAS) is a composite of scores on a scale of 0 (none) to 3 (intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch, measured twice daily (morning and evening). Daily UAS is the average of morning and evening scores (ranging from 0-6) and the UAS7 is the sum of the daily UAS over 7 days (ranging from 0-42). Baseline UAS7 is calculated using data from the 7 days prior to the first treatment date. A higher UAS indicates more urticaria activity. A negative change score indicates improvement.
Time frame: Week 12
Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With a UAS7 Less Than or Equal to 6 at Week 12 | 19.0 Percentage of participants |
| Omalizumab 75 mg | Percentage of Participants With a UAS7 Less Than or Equal to 6 at Week 12 | 26.8 Percentage of participants |
| Omalizumab 150 mg | Percentage of Participants With a UAS7 Less Than or Equal to 6 at Week 12 | 42.7 Percentage of participants |
| Omalizumab 300 mg | Percentage of Participants With a UAS7 Less Than or Equal to 6 at Week 12 | 65.8 Percentage of participants |
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 75 mg groups.p-value: 0.3419Cochran-Mantel-Haenszel
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 150 mg groups.p-value: 0.001Cochran-Mantel-Haenszel
Comparison: The null hypothesis is that there is no difference between placebo and omalizumab 300 mg groups.p-value: <0.0001Cochran-Mantel-Haenszel
Secondary
Percentage of Weekly Itch Severity Score MID Responders at Week 12
The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement. The MID response for weekly itch severity score was defined as a reduction from baseline in weekly itch severity score of 5 points or more. This outcome measure shows the percentage of participants classified as MID Responders at Week 12, meaning their weekly itch severity scores at Week 12 were at least 5 points lower than at Baseline.
Time frame: Baseline, Week 12
Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Weekly Itch Severity Score MID Responders at Week 12 | 48.1 Percentage of participants |
| Omalizumab 75 mg | Percentage of Weekly Itch Severity Score MID Responders at Week 12 | 56.1 Percentage of participants |
| Omalizumab 150 mg | Percentage of Weekly Itch Severity Score MID Responders at Week 12 | 69.5 Percentage of participants |
| Omalizumab 300 mg | Percentage of Weekly Itch Severity Score MID Responders at Week 12 | 78.5 Percentage of participants |
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 75 mg groups.p-value: 0.4366Cochran-Mantel-Haenszel
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 150 mg groups.p-value: 0.0045Cochran-Mantel-Haenszel
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 300 mg groups.p-value: <0.0001Cochran-Mantel-Haenszel
Secondary
Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12
The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement. The MID response for weekly itch severity score was defined as a reduction from baseline in weekly itch severity score of 5 points or more. The time to weekly itch severity score MID response was defined as the time (in weeks) from Day 1 to the study week when weekly itch severity score MID response was first achieved.
Time frame: by Week 12
Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12 | 4.0 Weeks |
| Omalizumab 75 mg | Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12 | 2.0 Weeks |
| Omalizumab 150 mg | Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12 | 2.0 Weeks |
| Omalizumab 300 mg | Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12 | 1.0 Weeks |
Comparison: The null hypothesis is that there is no difference between Placebo and Omalizumab 75 mg.p-value: 0.047895% CI: [1, 2.05]Cox proportional hazards model
Comparison: The null hypothesis is that there is no difference between the placebo and omalizumab 150 mg groups.p-value: 0.010195% CI: [1.12, 2.26]Cox proportional hazards model
Comparison: The null hypothesis is that there is no difference between placebo and omalizumab 300 mg groups.p-value: <0.000195% CI: [1.48, 3.03]Cox proportional hazards model